Clinical data collected from final patient, completing trial • Company plans PMA submission upon receipt of shelf-life stability data • PMA decision anticipated during the 2nd calendar quarter of 2018 Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 7 March 2017 — link here Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-03-07 15:01:492018-01-04 15:04:54Avita Medical Announces Last Patient Visit in U.S. Pivotal Trial
U.S. FDA Approves increased Compassionate Use Patient Cases and Sites for ReCell® in Life-Threatening Injuries • Up to 48 patients can now be treated at 15 US burnscenters • Increased use of ReCell® device by US surgeons under the Compassionate Use dispensations • Latest FDA approval separate to approval earlier in the month for Continued […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-03-06 19:21:512018-01-06 19:22:17U.S. FDA Approves increased Compassionate Use Patient Cases and Sites for ReCell® in Life-Threatening Injuries
CEO Shareholder Letter and Quarterly Report Dear Shareholder, link here As we conclude another quarter, it’s appropriate that I bring you, our owners, up-to-date on the progress Avita has made in recent months. US Approval Program Update The big goal that our team is working towards is entry to the US market, and I am […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-03-06 19:20:452018-01-06 19:21:34Quarterly Report and Update from CEO
Thursday, November 10, 2016 5:27 pm EST – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB US03211P1030 “AmpliPhi has made tremendous progress this quarter, demonstrated by the announcement of topline data from clinical trials of both of our lead development programs, including the first U.S.-based trial of AB-SA01” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation […]
CATEGORY: Featured Thursday, November 17, 2016 8:45 am EST – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB US03211P1030 SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics, today announced the pricing of an underwritten public offering of 5,335,000 shares of its […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-03-06 19:15:472018-01-06 19:16:46AmpliPhi Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
Digital health technology company, Adherium Limited, has appointed Scott Fleming as Senior Vice President of Business Development, Europe with immediate effect. – link here Background Adherium is a provider of digital health solutions to patients, pharmaceutical companies, healthcare providers and contract research organizations. Boasting the broadest range of “smart” medication sensors for respiratory medications globally, […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-03-06 15:57:282018-01-04 15:58:47Adherium Appoints Digital Health Pioneer to Lead European Business Development
Digital monitoring device proven to increase adherence and reduce hospital visits – link here The National Institute for Clinical Excellence (NICE) has recognised digital platform Smartinhaler as the most effective means of improving asthma medication adherence in new guidance. The Medtech Innovation Briefing – designed to accelerate NHS access to innovation in new treatments and […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-03-06 15:55:502018-01-04 15:57:10NICE recognises Smartinhaler as best practice for asthma care
23 February 2017: Adherium Limited (ASX : ADR), link here a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced the appointment of a new Vice President of Business Development for its key markets outside of North America and Europe. Erin Wansbrough will lead Adherium’s partnering and market […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-02-23 15:24:532018-01-04 15:51:53Adherium Expands Its International Presence, Announces Senior Appointment
CATEGORY: Featured Thursday, February 23, 2017 6:50 am EST – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “In 2017, AmpliPhi plans to initiate phage therapy studies in several patient groups, which we expect will mark a key inflection point for AmpliPhi and the phage therapy field” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-02-23 15:13:132018-01-04 15:16:33AmpliPhi Biosciences Establishes Scientific Advisory Board and Appoints Dr. Timothy Lu of MIT and Broad Institute as SAB Chairman
DUBLIN, Ireland, Feb. 22, 2017 (GLOBE NEWSWIRE) –Link here Nexvet Biopharma (Nasdaq:NVET) today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, Massachusetts on Monday, March 6th at 1:20PM ET. Dr. Heffernan will discuss Nexvet’s pivotal-stage clinical programs for […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-02-22 15:05:162018-01-05 19:43:46Nexvet to Present at the Cowen and Company 37th Annual Health Care Conference
Avita Medical Announces Last Patient Visit in U.S. Pivotal Trial
/in Portfolio CompaniesClinical data collected from final patient, completing trial • Company plans PMA submission upon receipt of shelf-life stability data • PMA decision anticipated during the 2nd calendar quarter of 2018 Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 7 March 2017 — link here Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused […]
U.S. FDA Approves increased Compassionate Use Patient Cases and Sites for ReCell® in Life-Threatening Injuries
/in Avita Medical, Portfolio CompaniesU.S. FDA Approves increased Compassionate Use Patient Cases and Sites for ReCell® in Life-Threatening Injuries • Up to 48 patients can now be treated at 15 US burnscenters • Increased use of ReCell® device by US surgeons under the Compassionate Use dispensations • Latest FDA approval separate to approval earlier in the month for Continued […]
Quarterly Report and Update from CEO
/in Avita Medical, Portfolio CompaniesCEO Shareholder Letter and Quarterly Report Dear Shareholder, link here As we conclude another quarter, it’s appropriate that I bring you, our owners, up-to-date on the progress Avita has made in recent months. US Approval Program Update The big goal that our team is working towards is entry to the US market, and I am […]
AmpliPhi Biosciences Reports Third Quarter 2016 Financial Results and Provides Corporate Update
/in Armata Pharmaceuticals, Portfolio CompaniesThursday, November 10, 2016 5:27 pm EST – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB US03211P1030 “AmpliPhi has made tremendous progress this quarter, demonstrated by the announcement of topline data from clinical trials of both of our lead development programs, including the first U.S.-based trial of AB-SA01” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation […]
AmpliPhi Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
/in Armata Pharmaceuticals, Portfolio CompaniesCATEGORY: Featured Thursday, November 17, 2016 8:45 am EST – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB US03211P1030 SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics, today announced the pricing of an underwritten public offering of 5,335,000 shares of its […]
Adherium Appoints Digital Health Pioneer to Lead European Business Development
/in Portfolio CompaniesDigital health technology company, Adherium Limited, has appointed Scott Fleming as Senior Vice President of Business Development, Europe with immediate effect. – link here Background Adherium is a provider of digital health solutions to patients, pharmaceutical companies, healthcare providers and contract research organizations. Boasting the broadest range of “smart” medication sensors for respiratory medications globally, […]
NICE recognises Smartinhaler as best practice for asthma care
/in Portfolio CompaniesDigital monitoring device proven to increase adherence and reduce hospital visits – link here The National Institute for Clinical Excellence (NICE) has recognised digital platform Smartinhaler as the most effective means of improving asthma medication adherence in new guidance. The Medtech Innovation Briefing – designed to accelerate NHS access to innovation in new treatments and […]
Adherium Expands Its International Presence, Announces Senior Appointment
/in Portfolio Companies23 February 2017: Adherium Limited (ASX : ADR), link here a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced the appointment of a new Vice President of Business Development for its key markets outside of North America and Europe. Erin Wansbrough will lead Adherium’s partnering and market […]
AmpliPhi Biosciences Establishes Scientific Advisory Board and Appoints Dr. Timothy Lu of MIT and Broad Institute as SAB Chairman
/in Portfolio CompaniesCATEGORY: Featured Thursday, February 23, 2017 6:50 am EST – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “In 2017, AmpliPhi plans to initiate phage therapy studies in several patient groups, which we expect will mark a key inflection point for AmpliPhi and the phage therapy field” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE […]
Nexvet to Present at the Cowen and Company 37th Annual Health Care Conference
/in Pharmamark, Portfolio CompaniesDUBLIN, Ireland, Feb. 22, 2017 (GLOBE NEWSWIRE) –Link here Nexvet Biopharma (Nasdaq:NVET) today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, Massachusetts on Monday, March 6th at 1:20PM ET. Dr. Heffernan will discuss Nexvet’s pivotal-stage clinical programs for […]